Clinical Trial Results:
A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination in healthy infants aged 6-12 weeks at the time of first vaccination in the Rota-036 study (102247) in Finland.
Summary
|
|
EudraCT number |
2006-006552-36 |
Trial protocol |
FI |
Global end of trial date |
08 Aug 2007
|
Results information
|
|
Results version number |
v1 |
This version publication date |
23 Jul 2016
|
First version publication date |
23 Jul 2016
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
109810
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT00420316 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
GlaxoSmithKline Biologicals
|
||
Sponsor organisation address |
Rue de l’Institut 89, Rixensart, Belgium, B-1330
|
||
Public contact |
Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
|
||
Scientific contact |
Clinical Trials Call Center, GlaxoSmithKline Biologicals, 044 2089-904466, GSKClinicalSupportHD@gsk.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
08 Aug 2007
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
08 Aug 2007
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
08 Aug 2007
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
•To assess the efficacy of GSK Biologicals’ HRV vaccine with respect to any rotavirus gastroenteritis (RV GE) episodes caused by the circulating wild-type RV strains during the follow-up period.
|
||
Protection of trial subjects |
All subjects in the primary study (2004-001175-19) were supervised for 30 minutes after vaccination/product administration with appropriate medical treatment readily available. Vaccines/products were administered by qualified and trained personnel. Vaccines/products were administered only to eligible subjects that had no contraindications to any components of the vaccines/products.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
12 Feb 2007
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Finland: 1613
|
||
Worldwide total number of subjects |
1613
|
||
EEA total number of subjects |
1613
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
1613
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
- | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Overall study (overall period)
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
HRV Group | ||||||||||||||||||
Arm description |
Subjects who received 2 oral doses of HRV vaccine in the primary study (102247) | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Rotarix
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
Live attenuated human rotavirus (HRV) vaccine
|
||||||||||||||||||
Pharmaceutical forms |
Powder for oral solution
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Oral administration of 2 doses of HRV vaccine in the primary study. No vaccine was administered during this extension study.
|
||||||||||||||||||
Arm title
|
Placebo Group | ||||||||||||||||||
Arm description |
Subjects who received 2 oral doses of placebo in the primary study (102247) | ||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||
Investigational medicinal product name |
Placebo
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
Live attenuated human rotavirus (HRV) vaccine
|
||||||||||||||||||
Pharmaceutical forms |
Oral liquid
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Oral administration of 2 doses of placebo in the primary study. No vaccine was administered during this extension study.
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
HRV Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who received 2 oral doses of HRV vaccine in the primary study (102247) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects who received 2 oral doses of placebo in the primary study (102247) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
HRV Group
|
||
Reporting group description |
Subjects who received 2 oral doses of HRV vaccine in the primary study (102247) | ||
Reporting group title |
Placebo Group
|
||
Reporting group description |
Subjects who received 2 oral doses of placebo in the primary study (102247) |
|
||||||||||
End point title |
Number of subjects with any rotavirus gastroenteritis (RV GE) caused by the circulating wild-type rotavirus strain. | |||||||||
End point description |
Number of subjects experiencing diarrhoea with or without vomiting. Two occurrences of diarrhoea were classified as separate episodes if there were 5 or more diarrhoea-free days between the episodes.
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
During the study period for the long-term follow-up (i.e. 6 months)
|
|||||||||
|
||||||||||
Statistical analysis title |
Vaccine efficacy with respect to any RV GE | |||||||||
Statistical analysis description |
Vaccine efficacy with respect to any rotavirus gastroenteritis (RV GE) caused by the circulating wild-type rotavirus strain. Vaccine efficacy (VE) was defined as the percent reduction in the frequency of the relevant outcome variable in vaccinated subjects compared with those subjects who received placebo.
|
|||||||||
Comparison groups |
HRV Group v Placebo Group
|
|||||||||
Number of subjects included in analysis |
1590
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other | |||||||||
P-value |
= 0.691 | |||||||||
Method |
Fisher exact | |||||||||
Parameter type |
Percent reduction | |||||||||
Point estimate |
34.3
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-348.7 | |||||||||
upper limit |
88.9 |
|
||||||||||
End point title |
Number of subjects with severe rotavirus gastroenteritis (RV GE) caused by the wild-type rotavirus strain | |||||||||
End point description |
Number of subjects experiencing an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system)
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
During the study period for the long-term follow-up (i.e. 6 months)
|
|||||||||
|
||||||||||
Statistical analysis title |
Vaccine efficacy with respect to severe RV GE | |||||||||
Statistical analysis description |
Vaccine efficacy with respect to severe rotavirus gastroenteritis (RV GE) caused by the circulating wild-type rotavirus strain. Vaccine efficacy (VE) was defined as the percent reduction in the frequency of the relevant outcome variable in vaccinated subjects compared with those subjects who received placebo.
|
|||||||||
Comparison groups |
HRV Group v Placebo Group
|
|||||||||
Number of subjects included in analysis |
1590
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other | |||||||||
P-value |
= 0.551 | |||||||||
Method |
Fisher exact | |||||||||
Parameter type |
Percent reduction | |||||||||
Point estimate |
50.7
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-3769.6 | |||||||||
upper limit |
99.4 |
|
|||||||||||||
End point title |
Number of subjects with any rotavirus gastroenteritis (RV GE) caused by the wild-type rotavirus strain of serotype G1 | ||||||||||||
End point description |
Any RV GE was defined as the number of subjects experiencing diarrhoea with or without vomiting. Two occurrences of diarrhoea were classified as separate episodes if there were 5 or more diarrhoea-free days between the episodes.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
During the study period for the long-term follow-up (i.e. 6 months)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Vaccine efficacy with respect to any RV GE | ||||||||||||
Statistical analysis description |
Vaccine efficacy with respect to any rotavirus gastroenteritis (RV GE) caused by the wild-type rotavirus strain of serotype G1.
Vaccine efficacy (VE) was defined as the percent reduction in the frequency of the relevant outcome variable in vaccinated subjects compared with those subjects who received placebo.
|
||||||||||||
Comparison groups |
HRV Group v Placebo Group
|
||||||||||||
Number of subjects included in analysis |
1590
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.109 | ||||||||||||
Method |
Fisher exact | ||||||||||||
Parameter type |
Percent reduction | ||||||||||||
Point estimate |
100
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-162.5 | ||||||||||||
upper limit |
100 |
|
|||||||||||||
End point title |
Number of subjects with any and severe rotavirus gastroenteritis (RV GE) caused by the wild-type rotavirus strain of serotype G1 | ||||||||||||
End point description |
Severe RV GE was defined as the number of subjects experiencing an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system)
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
During the study period for the long-term follow-up (i.e. 6 months)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Vaccine efficacy with respect to severe RV GE | ||||||||||||
Statistical analysis description |
Vaccine efficacy with respect to severe rotavirus gastroenteritis (RV GE) caused by the wild-type rotavirus strain of serotype G1. Vaccine efficacy (VE) was defined as the percent reduction in the frequency of the relevant outcome variable in vaccinated subjects compared with those subjects who received placebo.
|
||||||||||||
Comparison groups |
HRV Group v Placebo Group
|
||||||||||||
Number of subjects included in analysis |
1590
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 0.33 | ||||||||||||
Method |
Fisher exact | ||||||||||||
Parameter type |
Percent reduction | ||||||||||||
Point estimate |
100
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-1822.5 | ||||||||||||
upper limit |
100 |
|
|||||||||||||
End point title |
Number of subjects with any rotavirus gastroenteritis (RV GE) caused by the wild-type rotavirus strain of non-G1 serotype | ||||||||||||
End point description |
Any RV GE was defined as the number of subjects experiencing diarrhoea with or without vomiting. Two occurrences of diarrhoea were classified as separate episodes if there were 5 or more diarrhoea-free days between the episodes.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
During the study period for the long-term follow-up (i.e. 6 months)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Vaccine efficacy with respect to any RV GE | ||||||||||||
Statistical analysis description |
Vaccine efficacy with respect to any rotavirus gastroenteritis (RV GE) caused by the wild-type rotavirus strain of non-G1 serotype. Vaccine efficacy (VE) was defined as the percent reduction in the frequency of the relevant outcome variable in vaccinated subjects compared with those subjects who received placebo.
|
||||||||||||
Comparison groups |
HRV Group v Placebo Group
|
||||||||||||
Number of subjects included in analysis |
1590
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 1 | ||||||||||||
Method |
Fisher exact | ||||||||||||
Parameter type |
Percent reduction | ||||||||||||
Point estimate |
-97.2
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-9610.8 | ||||||||||||
upper limit |
80.5 |
|
|||||||||||||
End point title |
Number of subjects with severe rotavirus gastroenteritis (RV GE) caused by the wild-type rotavirus strain of non-G1 serotype | ||||||||||||
End point description |
Severe RV GE was defined as the number of subjects experiencing an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system)
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
During the study period for the long-term follow-up (i.e. 6 months)
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Vaccine efficacy with respect to severe RV GE | ||||||||||||
Statistical analysis description |
Vaccine efficacy with respect to severe rotavirus gastroenteritis (RV GE) caused by the wild-type rotavirus strain of non-G1 serotype. Vaccine efficacy (VE) was defined as the percent reduction in the frequency of the relevant outcome variable in vaccinated subjects compared with those subjects who received placebo.
|
||||||||||||
Comparison groups |
Placebo Group v HRV Group
|
||||||||||||
Number of subjects included in analysis |
1590
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
other | ||||||||||||
P-value |
= 1 | ||||||||||||
Method |
Fisher exact | ||||||||||||
Parameter type |
Percent reduction | ||||||||||||
Point estimate |
0
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0 | ||||||||||||
upper limit |
98.7 |
|
||||||||||
End point title |
Number of subjects with severe gastroenteritis (GE) | |||||||||
End point description |
Severe GE was defined as a GE episode requiring hospitalization and/or re-hydration therapy in a medical facility
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
During the study period for the long-term follow-up (i.e. 6 months)
|
|||||||||
|
||||||||||
Statistical analysis title |
Vaccine efficacy with respect to severe GE | |||||||||
Statistical analysis description |
Vaccine efficacy with respect to severe gastroenteritis (GE).Vaccine efficacy (VE) was defined as the percent reduction in the frequency of the relevant outcome variable in vaccinated subjects compared with those subjects who received placebo.
|
|||||||||
Comparison groups |
HRV Group v Placebo Group
|
|||||||||
Number of subjects included in analysis |
1590
|
|||||||||
Analysis specification |
Pre-specified
|
|||||||||
Analysis type |
other | |||||||||
P-value |
= 0.817 | |||||||||
Method |
Fisher exact | |||||||||
Parameter type |
Percent reduction | |||||||||
Point estimate |
-23.2
|
|||||||||
Confidence interval |
||||||||||
level |
95% | |||||||||
sides |
2-sided
|
|||||||||
lower limit |
-287.7 | |||||||||
upper limit |
54.8 |
|
||||||||||
End point title |
Number of subjects reporting serious adverse events (SAEs). | |||||||||
End point description |
An SAE was any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
During the study period for the long-term follow-up (i.e. 6 months)
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of subjects reporting Intussusception (IS) | |||||||||
End point description |
Intussusception is the telescoping of the intestine.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
During the period from the end of the second follow-up period up to the start of the study (end of July 2006 to beginning of January 2007)
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information [1]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Serious adverse events (SAEs): during the study period for the long-term follow-up (i.e. 6 months)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
The number of occurrences reported for solicited symptoms, adverse events, and serious adverse events were not available for posting. The number of subjects affected by each specific event was indicated as the number of occurrences.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
11.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
HRV Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo Group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: As per protocol, there were no non-serious adverse events planned to be assessed in this study. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |